CAR T Cell Therapy Transforming Combination Cancer Therapies Research – BioSpace

CAR T Cell Therapies Driving New Era Of Combination Cancer Therapies Says Kuick Research

Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:

Download Report:

https://www.kuickresearch.com/report-combination-cancer-therapy-market

Chimeric antigen receptor (CAR) T cell therapy has emerged out to revolutionary pillar in the management of cancer owing to its ability to produce durable clinical response. The recently developed CAR T cell therapy is a novel immunotherapeutic approach which involves genetic modification of patients autologous T cells to express CAR specific tumor antigen, following by ex vivo expansion and re-infusion back into patients. Till date, cocktail of CAR T cell therapies have been granted approval by regulatory bodies which have been indicated for the management of hematological malignancies such as lymphoma, leukemia, and multiple myeloma.

Although these have shown promising response in the management of hematological malignancies, however their role in solid tumors possesses several limitations. To mitigate these limitations, researchers have developed new combinational approaches to increase clinical outcomes in both hematological malignancies and solid tumors. For instance, recent clinical trial evaluated the safety and efficacy of the combination of anti-CD19 CAR T cells with ibrutinib in r/r chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with partial response or stable disease after ibrutinib monotherapy, showing a high rate of sustained responses with the combination therapy. The study results demonstrated rapid tumor progression after interrupting of treatment with ibrutinib in CLL patients. Further, another clinical trial studies demonstrated that simultaneous administration of ibrutinib with CAR T cells resulted in higher rates of minimal residual disease (MRD) negative response.

Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:

Download Report: https://www.kuickresearch.com/report-car-t-cell-therapy-market

In another study by researchers on pancreatic ductal adenocarcinoma or colorectal cancer, OV Ad-EGFR BITE adenovirus, which is armed by EGFR-targeting, a bispecific T-cell engager was used. The data showed that concomitant use of this engineered virus and CAR T cells containing 4-1BB endodomain and targeting folate receptor alpha (FR-) antigen improved the function of CAR T cells. This is because of the BITE secretion of the contaminated cancer cells.

The encouraging response of combinational CAR T cell therapies has gained significant interest from pharmaceutical giants to invest in this segment. Currently, only a few clinical trials have been initiated by pharmaceutical companies which are evaluating the role of CAR T cell therapies in combination with oncolytic virus therapy and other cancer targeting regimens. The key companies in the market include Transgene, Merck, Janssen Pharmaceutical, Mustang Bio, and others. The pharmaceutical giants have also adopted strategic alliances including collaboration, partnership, or joint ventures to drive the research and development activities in this domain.

Recently in 2022, Transgene and PersonGen Biotherapeutics announced strategic research collaboration to access the safety and effectiveness of combination therapy associating PersonGen's TAA06 CAR-T cell injection with intravenous (IV) administration of an armed oncolytic virus, from Transgenes Invir.IO platform, in solid tumors including pancreatic cancer and brain glioma. The collaboration aims to demonstrate the combinations likely synergistic mechanisms to potentiate CAR-T cell therapy. Additionally, Celyad Oncology entered into clinical trial collaboration with Merck. Under the terms of agreement, the company will conduct phase-I KEYNOTE-B79 clinical trial, which will evaluate Celyad Oncologys investigational non-gene edited allogeneic CAR T candidate, CYAD-101, following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapy with Mercks Keytrudain refractory metastatic colorectal cancer (mCRC) patients with microsatellite stable (MSS) / mismatch-repair proficient (pMMR) disease.

As per our report findings, the global cancer combination immunotherapy market is expected to surpass US$ XX Billion by 2028. The rising prevalence of various cancers such as hematological malignancies among the global population and rising adoption of CAR T cell therapy to treat cancer is boosting the growth of market. The rising awareness regarding the benefits of immunotherapy therapy over traditional therapies is further driving the demand of cancer combination immunotherapy among cancer patients. The immunotherapy in pipeline is likely to provide more treatment choices and better patient outcomes, which will further propel the growth of market.

Contact:

Neeraj Chawla

Kuick research

Research Head

+91-981410366

neeraj@kuickresearch.com

https://www.kuickresearch.com

Read the rest here:
CAR T Cell Therapy Transforming Combination Cancer Therapies Research - BioSpace